Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory or recurrent Plantar Warts.~* No wart treatment for the last 12 weeks~* Healthy male or non-pregnant, non-lactating female aged ≥ 18 years or greater~* If female of childbearing potential, use an acceptable form of birth control during the study~* Provide written informed consent or (HIPAA consent/authorization, as applicable~Exclusion Criteria:~* Concurrent medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe~* Female subjects who are breast-feeding or planning to become pregnant~* Patients with a history of allergy to silver or fruits~* Subjects with clinically significant unstable medical disorder, life threatening disease, or current malignancies~* Subjects with History of Alcohol abuse or other drug abuse within 2 years prior to Randomization~* Subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment~* Concomitant Medications: any other wart therapy is prohibited during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Nowarta110 3 drops (Type: EXPERIMENTAL): Nowarta110 3 drops administration
- Nowarta110 6 drops (Type: EXPERIMENTAL): Nowarta110 6 drops administration
- Nowarta110 10 drops (Type: EXPERIMENTAL): Nowarta110 10 drops administration

Based on this trial design, predict the completion outcome and termination type (if applicable).